Nehal Lakhani, MD
Hematology & Oncology · Grand Rapids, MINPI 1598986986
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,335 of the $12,578 with a category attached, or 82.2%. 9 manufacturers reported payments, led by SK Life Science, Inc. at 42.9% of the total.
Across 17 payments — averaging $739.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$5K
- Janssen Global Services, LLC$5K
- Eli Lilly$2K
- Foundation Medicine, Inc.$260
- AstraZeneca$208
- Boehringer Ingelheim$103
- plus $156 from 3 others
Across 2,418 payments — averaging $6202.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.2M
- Seagen Inc.$2.2M
- Merck$2M
- Regeneron$1.9M
- Janssen Research & Development, LLC$1.6M
- Pfizer$1.1M
- plus $4M from 21 others
What the payments were for
- Consulting fees$10,33582%
- Travel & lodging$1,50812%
- Food & beverage$7356%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 1 | $5,400 |
| Janssen Global Services, LLC | 1 | $4,935 |
| Eli Lilly | 6 | $1,516 |
| Foundation Medicine, Inc. | 3 | $260 |
| AstraZeneca | 2 | $208 |
| Boehringer Ingelheim | 1 | $103 |
| GSK | 1 | $77 |
| Regeneron | 1 | $55 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$5,400
- FOUNDATIONONE$241
- FOUNDATIONONE HEME$241
- FOUNDATIONONE CDX$241
- FOUNDATIONFOCUS$241
- FOUNDATIONONE LIQUID$241
- LYNPARZA$121
How this compares
$12,578 in reported general payments places this provider in the 85th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 12 | $291 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 17 | $256 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $173 |
| Prochlorperazine Maleate | 16 | $140 |
| Prednisone | 15 | $89 |
| Meloxicam | 11 | $76 |
| Amlodipine Besylate | 12 | $62 |
| Levothyroxine Sodium | 13 | $34 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Grand Rapids
- Sreenivasa ChandanaGrand Rapids$305K
- Eric SantosGrand Rapids$11K
- Erin PettijohnGrand Rapids$10K
- Colin HardinGrand Rapids$10K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.